指甲花提取物(Lawsonia inermis Extract)

概要

基本信息

药物类型

中药

别名

Henna

靶点-

作用机制-

治疗领域

神经系统疾病皮肤和肌肉骨骼疾病泌尿生殖系统疾病+ [2]

在研适应症-

非在研适应症

皮炎皮疹手足综合症+ [3]

原研机构-

在研机构-

非在研机构

Islamic Azad University

Cyprus University of Technology

Yazd University

+ [1]

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与指甲花提取物相关的临床试验

IRCT20191106045356N21 / Suspended临床3期IIT

Formulation of a topical gel containing Lawsonia inermis extract and Aloe vera and evaluation its effects on the healing process of second degree burns: A randomized double_blinded placebo_controlled trial.

开始日期2024-10-21

申办/合作机构-

CTRI/2024/09/074530 / Not yet recruiting临床2期IIT

Formulation and evaluation of topical preparation of Lawsonia inermis L. (Lythraceae) for the prevention of capecitabine induced hand-foot syndrome in Cancer patients - NIL

开始日期2024-10-07

申办/合作机构-

IRCT20191106045356N20 / Recruiting临床3期IIT

Formulation of a topical gel containing Lawsonia inermis and Crocin and evaluation its effects on preventing radiation-induced dermatitis in breast cancer patients: A randomized double-blinded placebo-controlled trial.

开始日期2024-08-21

申办/合作机构-

100 项与指甲花提取物相关的临床结果

登录后查看更多信息

100 项与指甲花提取物相关的转化医学

登录后查看更多信息

100 项与指甲花提取物相关的专利（医药）

登录后查看更多信息

47

项与指甲花提取物相关的文献（医药）

2023-09-01·Journal of Ethnopharmacology

The effect of a topical formulation from Lawsonia inermis L. (henna) on pain intensity in patients with chronic sciatica: A randomized double-blind clinical trial

Article

作者: Rahimi, Roja ; Raei, Mehdi ; Abbassian, Alireza ; Ostadrahimi, Nima ; Lavari, Narges

Chronic sciatica (CS) is a common condition of disability and pain.Lawsonia inermis L. (henna) is a medicinal plant that is commonly recommended in traditional Persian medicine textbooks for pain relief in patients with sciatica, particularly in the form of oil.This research was designed to investigate the efficacy of a topical formulation from henna on pain intensity in patients with CS.In a randomized, double-blind clin. study, 81 patients were randomly allocated to three groups to receive the topical henna formulation (aqueous extract of henna in sesame oil), sesame oil, or placebo, three times daily, for four weeks.The patients were assessed by visual analog scale (VAS), 36-item short form health survey (SF-36), and Oswestry disability index (ODI).There was a significant decrease in mean VAS in henna oil compared to sesame oil (p = 0.004) and placebo (p = 0.004).Significant improvements in total SF-36 scores were observed in henna oil and sesame oil compared to placebo (p = 0.011 and p = 0.025, resp.).Furthermore, ODI significantly decreased in henna oil compared to sesame oil (p < 0.001) and placebo (p = 0.005).Henna oil seems to be an effective treatment to reduce pain intensity in patients with CS.Moreover, it improves quality of life and functional ability.Further randomized controlled trials with longer intervention periods are recommended to confirm this efficacy.

2023-02-02·Cureus

Severe Hyperbilirubinemia Secondary to Henna Application in a Neonate With G6PD Deficiency: A Case Report and Literature Review

作者: Al-Hinai, Abdulhamid ; AlSawafi, Aza S

Henna is a natural product commonly used for cosmetics, healing, and social occasions in the Middle East and South Asian countries. It usually carries no significant medical complications in a healthy individual. However, henna in a patient with G6PD deficiency can cause serious medical complications, including severe hyperbilirubinemia and hemolytic anemia, due to its oxidative stress on the erythrocyte. This paper reports a previously undiagnosed G6PD deficient neonate who presented with severe hyperbilirubinemia without the classical laboratory findings of hemolytic anemia. In addition, we reviewed the literature and summarized the clinical and laboratory findings of 31 G6PD-deficient pediatric patients with henna-induced hemolytic anemia (HIHA). The reported adverse effects of HIHA included death (N: 2), kernicterus (N: 3), life-threatening hemolytic anemia that required blood transfusion (N: 9), and severe hyperbilirubinemia requiring exchange transfusion (N: 7). Although HIHA in G6PD deficiency is a well-known fact in the literature, we believe it is still under-reported. Given the high prevalence of G6PD deficiency and the widespread practice of henna application, we recommend avoiding it, especially in infancy, until the G6PD status is known. Society awareness should be raised about it.

2022-06-01·DARU Journal of Pharmaceutical Sciences4区 · 医学

Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical

4区 · 医学

Article

作者: Rasta, Sara ; Elyasi, Sepideh ; Taghizadeh-Kermani, Ali ; Hosseini, Sare

PURPOSEIn this clinical trial, we evaluated Alpha® ointment efficacy in prevention of capecitabine induced hand-foot syndrome (HFS) in patients with gastrointestinal or breast cancers, for the first time.METHODSDuring this pilot, randomized, triple-blinded, placebo-controlled clinical trial, the effect of Alpha® ointment (Lawsonia inermis 3 g and Curcuma longa 0.15 g/ 30 g) was assessed. It was applied on the palms and the soles, two times daily starting at the first day of chemotherapy for 4 consecutive courses. The severity of HFS was assessed at the end of the chemotherapy courses based on World Health Organization (WHO) scale and scored between 0-4.RESULTSNinety eligible patients were included randomly in the treatment or placebo group. Median WHO HFS grade was not significantly different between the two groups, during the follow-up period (P > 0.05). In the weekly assessment, the scores increased meaningfully in both the placebo and treatment groups, but there was a delay in HFS occurrence and deterioration in Alpha ointment group based on post hoc analysis.CONCLUSIONAdministration of Alpha® ointment containing henna and curcumin could not significantly prevent capecitabine induced HFS during 4 courses of treatment, but can somewhat delay its occurrence in patients with gastrointestinal or breast cancer.

100 项与指甲花提取物相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
坐骨神经痛	临床3期	伊朗	Tehran University of Medical Sciences	2021-10-11
皮炎	临床3期	伊朗	Yazd University	2021-08-21
宫颈炎	临床3期	伊朗	Yazd University	2021-08-06
皮疹	临床3期	伊朗	Islamic Azad University	2018-02-24
放射性皮炎	临床3期	伊朗	Islamic Azad University	2018-02-24
手足综合症	临床3期	塞浦路斯	Cyprus University of Technology	2017-06-01